We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » REMS Provision Left Out of PDUFA, GPhA Criticizes Lack of House Access
REMS Provision Left Out of PDUFA, GPhA Criticizes Lack of House Access
June 19, 2012
Generic-drug makers are raising concerns with their access to House user fee bill discussions because unlike the Senate, House lawmakers didn’t hold a joint meeting with the FDA, PhRMA and GPhA on certain cost-saving provisions of its FDA user fee bill.